These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 18024397

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Successful prolonged rituximab treatment for post-transplant lymphoproliferative disorder following living donor liver transplantation in a child.
    Hayashida M, Ogita K, Matsuura T, Takahashi Y, Nishimoto Y, Ohga S, Hara T, Soejima Y, Taketomi A, Maehara Y, Kohashi K, Tsuneyoshi M, Taguchi T.
    Pediatr Transplant; 2007 Sep; 11(6):671-5. PubMed ID: 17663692
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Intestinal perforation associated with rituximab therapy for post-transplant lymphoproliferative disorder after liver transplantation.
    Cornejo A, Bohnenblust M, Harris C, Abrahamian GA.
    Cancer Chemother Pharmacol; 2009 Sep; 64(4):857-60. PubMed ID: 19588139
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen.
    Fohrer C, Caillard S, Koumarianou A, Ellero B, Woehl-Jaeglé ML, Meyer C, Epailly E, Chenard MP, Lioure B, Natarajan-Ame S, Maloisel F, Lutun P, Kessler R, Moulin B, Bergerat JP, Wolf P, Herbrecht R.
    Br J Haematol; 2006 Sep; 134(6):602-12. PubMed ID: 16889621
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma.
    Pro B, Leber B, Smith M, Fayad L, Romaguera J, Hagemeister F, Rodriguez A, McLaughlin P, Samaniego F, Zwiebel J, Lopez A, Kwak L, Younes A.
    Br J Haematol; 2008 Nov; 143(3):355-60. PubMed ID: 18764869
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
    Kerl K, Prins C, Saurat JH, French LE.
    Br J Dermatol; 2006 Dec; 155(6):1197-200. PubMed ID: 17107389
    [Abstract] [Full Text] [Related]

  • 34. Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders.
    Ghobrial IM, Habermann TM, Maurer MJ, Geyer SM, Ristow KM, Larson TS, Walker RC, Ansell SM, Macon WR, Gores GG, Stegall MD, McGregor CG.
    J Clin Oncol; 2005 Oct 20; 23(30):7574-82. PubMed ID: 16186599
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type.
    Salar A, Domingo-Domenech E, Estany C, Canales MA, Gallardo F, Servitje O, Fraile G, Montalbán C.
    Cancer; 2009 Nov 15; 115(22):5210-7. PubMed ID: 19672998
    [Abstract] [Full Text] [Related]

  • 38. Novel treatment with rituximab of oropharyngeal posttransplant lymphoproliferative disorder after heart transplantation.
    Kaczmarek I, Beiras-Fernandez A, Sadoni S, Bengel D, Deutsch MA, Meiser B, Reichart B.
    Exp Clin Transplant; 2005 Dec 15; 3(2):381-4. PubMed ID: 16417448
    [Abstract] [Full Text] [Related]

  • 39. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.
    Knight JS, Tsodikov A, Cibrik DM, Ross CW, Kaminski MS, Blayney DW.
    J Clin Oncol; 2009 Jul 10; 27(20):3354-62. PubMed ID: 19451438
    [Abstract] [Full Text] [Related]

  • 40. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.
    Martín A, Conde E, Arnan M, Canales MA, Deben G, Sancho JM, Andreu R, Salar A, García-Sanchez P, Vázquez L, Nistal S, Requena MJ, Donato EM, González JA, León A, Ruiz C, Grande C, González-Barca E, Caballero MD, Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL/TAMO Cooperative Group).
    Haematologica; 2008 Dec 10; 93(12):1829-36. PubMed ID: 18945747
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.